Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma

NCT01534585 | Completed Phase 1 DMC

• 1 other identifier: YHH-201201
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

Nasopharyngeal carcinoma (NPC) is a prevalent disease in southeast of China. Radiation therapy with or without chemotherapy is a standard therapy for nasopharyngeal cancer. Cytotoxic chemotherapy plays an important role in the curative treatment of advanced NPC. However, concurrent chemoradiotherapy increased significantly local and systemic toxic effects, which may preclude many patients from proceeding with combined therapy. The epidermal growth factor receptor(EGFR) gene is amplified in 40% and EGFR protein is overexpressed in over 80% of NPC. EGFR overexpression is also associated with shorter survival following chemoradiotherapy in locoregionally advanced NPC. And some basic researches have proved that EGFR tyrosine kinase inhibitors(TKIs) could increase the radiosensitivity and reduce the epithelial-mesenchymal transition (EMT) in NPC cell line. Moreover, distant metastases has been the major cause of treatment failure in NPC. Icotinib hydrochloride is a novel oral EGFR TKIs with low mammalian toxicity(made in China). But base on toxic effects of Icotinib, it may increase toxic effects about skin and mucosa in combination therapy with Icotinib and Intensity-modulated Radiotherapy (IMRT). The prospective study will assess the tolerability and efficacy of Icotinib combined with IMRT in patients with NPC. This regimen is of great interest and it has potential to alleviate the adverse effects, improve patient compliance and better therapeutic ratio.

Conditions

Nasopharyngeal Carcinoma

Keywords

nasopharyngeal carcinoma(NPC); Icotinib; Intensity Modulation Radiation Therapy(IMRT)

Outcome Measures

Primary Outcomes (2)

• Phase I: the maximum tolerated dose of Icotinib in combination with IMRT for NPC

  30 days

• Phase II: 2 years locoregional control rate

  Two years

Secondary Outcomes (5)

• The overall response rate (complete and partial response)

  1 month following treatment and then every 3 months

• The acute and late toxicity profile associated with the study regimen

  1 month following treatment and then every 3 months

• The duration of control of locoregional disease

  1 month following treatment and then every 3 months

• Overall survival, disease-free survival, and distant relapse rates

  At time of locoregional disease progression

• EGFR status in tissue and blood before treatment

  2 week of pretreatment

Interventions

Icotinib DRUG

Oral Icotinib begins on day 1 and continues until completion of radiotherapy. Phase I:The initial plan is to accrue 6 patients to each dose level (125mg, qd and bid and tid) in each cohort. If one or none of six patients have dose limiting toxicity (DLT), then escalation will proceed. If DLT occurs in two or more patients at a dose level, then escalation will be stopped. The dose level below that at which two of six patients experience a DLT is defined as the maximum-tolerated dose. A minimum of 4 weeks of observation is required after completion of radiation within each Icotinib dose level before accrual to the next level. Phase II:According to the maximum tolerated dose, 50 patients will been recruited.

Also known as: Conmana

intensity-modulated radiotherapy RADIATION

The nasopharyngeal regions and upper neck with IMRT plans will be generated and approved for each patient, whereas the low-neck and supraclavicular regions will be used with a conventional anterior field. A total of 70-76Gy at 2.12-2.3Gy/fraction/d will be given to the GTVnx, the GTVnd will receive 66-70Gy at 2.0-2.12Gy/fraction/d, the CTV1 will receive 60-66Gy at 1.8-2.0Gy/fraction/d, and the CTV2 received 56-60Gy at 1.7-1.8Gy/fraction/d with IMRT. The low-neck and supraclavicular regions will receive 50-60Gy at 2.0Gy/fraction/d with conventional radiotherapy. Target prescription dose and critical structures limit dose are planned according to the RTOG0225 trial.

Also known as: IMRT

Paclitaxel and Cisplatin DRUG

AC that consisted of two cycles of paclitaxel 135 mg/m2 on day 1 plus cisplatin 30 mg/m2 on days 1-3 will start 4 weeks after the end of CRT.

Quality of life OTHER

The EORTC QLQ-C30 and H\&N35 of the Chinese version, which is obtained from the Quality of Life Unit, EORTC Data Center in Brussels, Belgium, is available and easily completed by our patients are chosen for this study. Patients will complete the questionnaire before treatment and after treatment and one month after treatment and three months after treatment and one year after treatment.

Also known as: QoL

Epidermal growth factor receptor status GENETIC

EGFR expression and mutation before treatment.

Also known as: EGFR

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with histological proof of squamous carcinoma of the nasopharynx.
• Patients must have ECOG Performance Status of 0-1.
• Patients should have adequate bone marrow function defined as an absolute peripheral granulocyte count (AGC) of \>/= 1500 cells/mm3, platelet count of \>/= 100,000 cells/mm3; adequate hepatic function with bilirubin \</= 1.5mg/dl, AST and ALT \</= 2x the upper limit of normal; serum creatinine \</= 1.5mg/dl, creatinine clearance \>/= 50 ml/min and INR 0.8 - 1.2.
• Patients must sign a study specific informed consent form prior to study entry.

You may not qualify if:

• Evidence of metastases by clinical or radiographic examinations.
• History of malignancy other than non-melanoma skin cancer.
• Prior chemotherapy or anticancer biologic therapy for any type of cancer, or prior radiotherapy to the head and neck region except for radioactive iodine therapy.
• Patients with uncontrolled intercurrent disease.
• Patients with currently active malignancy.
• Pregnant or lactating women Female patients of childbearing potential who are unwilling to practice adequate contraception during study treatment and for two months after the last administration of study drug.

Sponsors & Collaborators

• Taizhou Hospital: lead

Study Sites (1)

Taizhou Hospital, Wenzhou Medical College

Taizhou, Zhejiang, 317000, China

Location

MeSH Terms

Conditions

Nasopharyngeal Carcinoma

Interventions

icotinib; Radiotherapy, Intensity-Modulated; TP protocol; Quality of Life

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Nasopharyngeal Neoplasms; Pharyngeal Neoplasms; Otorhinolaryngologic Neoplasms; Head and Neck Neoplasms; Neoplasms by Site; Nasopharyngeal Diseases; Pharyngeal Diseases; Stomatognathic Diseases; Otorhinolaryngologic Diseases

Intervention Hierarchy (Ancestors)

Radiotherapy, Conformal; Radiotherapy, Computer-Assisted; Radiotherapy; Therapeutics; Health Status; Demography; Epidemiologic Measurements; Public Health; Environment and Public Health

Study Officials

• Haihua Yang, MD.

  Department of Radiation Oncology, Taizhou Hospital, Wenzhou Medical College.

  STUDY DIRECTOR

• Wei Hu, MD.

  Department of Radiation Oncology, Taizhou Hospital, Wenzhou Medical College.

  STUDY CHAIR

• Wei Wang, BS

  Department of Radiation Oncology, Taizhou Hospital, Wenzhou Medical College.

  PRINCIPAL INVESTIGATOR

• Chao Zhou, MD.

  Department of Radiation Oncology, Taizhou Hospital, Wenzhou Medical College.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director of Radiotherapy Dept

Study Record Dates

• First Submitted: February 13, 2012
• First Posted: February 16, 2012
• Study Start: February 1, 2012
• Primary Completion: February 1, 2013
• Study Completion: February 1, 2015
• Last Updated: April 17, 2018

Record last verified: 2018-04

Locations

CN (1)